Na Wei

Check out the video below showcasing some of our latest and most technological Repligen products.

7

Latest on MDMA rejection; Novo vs. Lilly earnings; Recursion, Exscientia to merge; Q&A with Genentech CEO; and more https://lnkd.in/gRuf3XRp Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News

1

SFBN Feed: Arcellx and Gilead seek to unseat J&J-Legend in multiple myeloma https://lnkd.in/g_9CQUG2 SAN DIEGO — Gilead and Arcellx say their experimental multiple myeloma cell therapy anito-cel could be a safer rival to field leaders Legend Biotech and Johnson & Johnson. New results from a pivotal study of [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

1

Candid Therapeutics, a new San Diego biotech bent on becoming a leader in the emerging T-cell engager space, has unwrapped three new research collaborations focusing on autoimmune diseases. Candid will partner with EpimAb Biotherapeutics, Inc. , Nona Biosciences and Ab Studio to beef up its pipeline of bispecific antibodies. https://lnkd.in/eU4ktbC6

9

Lake N. Paul, PhD. is in San Diego at the Biotechnology Innovation Organization #BIO2024 conference meeting with colleagues & future clients. Connect with him in person to learn about how, as a Collaborative Research Organization, we are best positioned to support your analytical program. #aav #genetherapy #rarediseases #biophysics #STEM #STEMPhilly #biochemistry #celltherapy #bioanalysisllc #PhillyBusiness #phillyscience

9

I am on my way to embarking on an epic journey across the greater Los Angeles area, visiting some of the brightest minds at UCLA, Caltech, and several of the region’s top cancer hospitals, together with Chris Bishop. I’m beyond excited to dive deep into discussions on biofilm, sterility in gnotobiotic facilities, and microbiome analysis using microcalorimetry. But what excites me the most is sharing our abilities for rapid sterility testing. With our platform, we’re capable of detecting fewer than five microbial cells of most compendium organisms in under 24 hours — and even C. acnes, which has long been a challenge, within 60 hours. And yes, we’ve achieved this even in complex matrices like ATMPs! Looking forward to exchanging insights, sparking collaborations, and showing how we’re pushing the boundaries of microbial detection. Let’s connect if you’re in the area or want to learn more! #Innovation #Microbiology #SterilityTesting #Microcalorimetry #Biofilm #ATMP #gnotobiotic Symcel

54

2 Comments

Our team is proud to present our most recent publication: 👉 For patients with metastatic colorectal carcinoma, limited RAS pathway testing is standard of care for detection of primary resistance to anti-EGFR mAb therapy. 👉 We empirically evaluate the outcomes associated with a broader set of alterations that would biologically anticipate resistance (ERBB2, RTK, and RAS/PI3K) and found that empirical outcomes associated with these broader alterations similarly associates with limited clinical benefit from anti-EGFR therapy. 👉 Evaluating post-EGFR therapy specimens, we observe a greater prevalence in these alterations as well, temporally consistent with being resistance alterations. 👉 Because these alterations are not included in standard PCR panels, the results suggest greater utility for NGS testing at baseline for clinical decisions around anti-EGFR vs. anti-VEGF use. Ryon Graf, PhD, Matthew J. Emmett, MD, PhD, Samuel Klempner, Samantha Morley, Hanna Tukachinsky, and Alexa Schrock, PhD

69

"San Diago... which of course in German means..." (you can fill in the blank in your head if you know the reference 😂) But I AM in gorgeous San Diego! Please reach out if you've been curious about base editing and would like to have an in person seminar in the So Cal region this month! Why base editing for your therapeutic cell engineering pipelines? ⏲️ SAVE TIME- reduce timelines on multiplex edited cell products by up to 90% 💰 SAVE ON COSTS of manufacturing when less steps are required to reach the end product 💪 HEALTHIER CELL PRODUCTS - gene editing with our platform avoids double strand DNA breaks, reducing the risk of genomic translocations, reducing cytotoxicity, and supporting normal growth rates

23

1 Comment

<!-- Content start --> South San Francisco, CA — July 3, 2024 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial (first-line) treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (nSq NSCLC), did not meet its primary endpoints of progression-free survival (PFS) at its primary analysis with a hazard ratio (HR) of 1.27 [95% CI: 1.02,1.57] and overall survival (OS) at its first interim analysis with a HR of 1.33 [95% CI: 1.02, 1.73], which was immature. The combination of tiragolumab plus Tecentriq and chemotherapy showed reduced efficacy in both PFS and OS compared to the comparator arm in the intent-to-treat population, which includes Phase II and Phase III cohorts. The overall safety profile remains consistent with the safety profile previously observed for the combination of tiragolumab plus Tecentriq and chemotherapy, and no new or unexpected findings were identified. Based on these results, patients and investigators will be unblinded and we intend to halt the study. A communication will be sent to the investigators and results will be shared with health authorities and subsequently presented at an upcoming medical meeting. “These results are disappointing as it was our hope that this combination might yield improved outcomes for people living with metastatic non-squamous lung cancer,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “We are thankful to all of the patients and healthcare professionals involved in the study, and we will leverage the learnings to inform our scientific understanding of the anti-TIGIT pathway and new avenues in cancer research.” Ongoing Phase III studies are investigating treatment settings and indications distinct from SKYSCRAPER-06. Based on today’s results, we will evaluate any relevant changes needed to the ongoing tiragolumab program. About SKYSCRAPER-06 study SKYSCRAPER-06 is a global Phase II/III, randomized, placebo-controlled and double-blinded study evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy as an initial (first-line) treatment versus pembrolizumab and chemotherapy in 542 people with non-squamous non-small cell lung cancer. Primary endpoints are overall survival (OS) and progression-free survival (PFS). About tiragolumab Tiragolumab is an investigational novel immune checkpoint inhibitor with an intact Fc region. Tiragolumab selectively binds to TIGIT, a novel inhibitory immune checkpoint which suppresses the immune response to cancer. Based on preclinical research, tiragolumab is thought to work as an immune amplifier with other cancer immunotherapies such as Tecentriq® (atezolizumab). The TIGIT pathway is distinct but

1

A new #CRISPR-based clinical trial for #SickleCell disease is enrolling at UCSF. This is the first therapy in the U.S. to apply non-viral CRISPR gene editing to directly correct the genetic mutation that causes the disease. Read more: https://ow.ly/Smry50UfZi1

32

🌟 Best of #ASMS2024 🌟 Fintiede Solutions is thrilled to share the groundbreaking advancements unveiled by Evosep at the #ASMS2024 conference in Anaheim! Evosep continues to push the boundaries in the field of proteomics, introducing innovations that are set to transform research and clinical diagnostics. 🔬 Key Innovations Announced: Fully Automated Workflows: - Capable of processing over 500 plasma samples per day. - Maximizes efficiency and minimizes manual intervention. - Ideal for accelerating drug discovery and supporting large-scale translational research. - Reduces cost per sample and environmental impact. Whisper™ Zoom Methods: - Enhances scalability and sensitivity for detailed and accurate proteomic analyses. - Unlocks the ability to detect low-abundant proteins and identify novel biomarkers. - Facilitates deeper biological insights into disease pathways. Evosep Biolabs: Center of Excellence for High Throughput Proteomics: - Specializes in high-throughput proteomics with automated sample preparation. - Offers access to state-of-the-art LC-MS/MS workflows and expert assay development. - Provides scalable capacity for outsourcing proteomics research projects. 🏆 Impact and Vision: Evosep's innovations are designed to make clinical proteomics 100x more robust and 10x faster, revolutionizing the landscape of proteomics research. These advancements are particularly aimed at accelerating drug discovery and enhancing proteomics-based diagnostics, ultimately improving patient care. We are proud to be part of this journey and look forward to the incredible breakthroughs these technologies will enable in the near future. #Evosep #Proteomics #ASMS2024 #ScientificInnovation #DrugDiscovery #TranslationalResearch #Biomarkers #ClinicalDiagnostics #automation #whisper

2